DHA (nutritional supplement) or placebo
Dietary Supplementoral 900mg/day
NCT Number: NCT00278135
The purpose of this study is to investigate the effect of docosahexaenoic acid (DHA, 22:6n-3) in improving cognitive functions in subjects with age-related cognitive decline. DHA is a long chain omega-3 fatty acid (LC-PUFA) that plays an important role in neural and visual development and cardiovascular health.
Looking for future studies?
Notify Me55 year and older
All sexes
Interventional
Not applicable
Pivotal Research Center, Mesa, Arizona, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
oral 900mg/day
Time frame: 24 weeks
Time frame: 24 weeks
dsm-firmenich Switzerland AG
Industry
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of DHA on Cognitive Functions in the Elderly
Acronym: MIDAS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04910399
Age-related Cognitive Decline, Cognition Disorders
Bordeaux, France
View Trial DetailsNCT02185222
Age-related Cognitive Decline, Cognition Disorders
Angers, France
View Trial DetailsNCT06820710
Age-related Cognitive Decline, Aging
Cremona, Italy
View Trial DetailsNCT05599490
Age-related Cognitive Decline
Iowa City, Iowa, United States
View Trial Details